The fund would hold Injective Protocol’s native token, INJ, and stake a portion of it via approved validator providers Injective’s price surged up to 14% following the news, currently hovering around $14 Canary Capital has similar filings underway for assets such as Solana, XRP, Hedera, SUI, and Tron Canary Capital, a Delaware-based asset manager, has filed an S‑1 registration with the US SEC for the Canary Staked INJ ETF . This marks the first-ever US ETF that offers exposure to INJ, Injective Protocol’s native token, plus on-chain staking rewards. The fund would hold INJ and stake a portion of it via approved validator providers, passing annual yields (estimated to be around 10% to 12%) to ETF shareholders. Injective’s price surged up to 14% following the news, currently hovering around $14. Also, DEX volumes of Injective have tripled recently (from $0.4 million to $1.1 million daily), and TVL (Total Value Locked) has climbed to roughly $109 million, which is close to its early 2025 peak. As Injective trades within the critical $14-$16 range, its performance here will likely shape its immediate future, especially as excitement around the new ETF … The post Staked Injective ETF Filed by Canary Capital: Can INJ Reach $16? appeared first on Coin Edition .
